Glooko Announces Digital Health Collaboration with Eli Lilly s Connected Insulin Pen Solutions in Global Markets
News provided by
Share this article
Share this article
GOTHENBURG, Sweden, May 6, 2021 /PRNewswire/ Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, today announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly s connected insulin pen solutions. The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the U.S., via integration of Lilly s Tempo Pen™ and Tempo Smart Button™ (currently in late-stage development) with Glooko s platform.
What We Should Know:
– Glooko Inc., a provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions.
– The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the U.S., via integration of Lilly’s Tempo Pen™ and Tempo Smart Button™ (currently in late-stage development) with Glooko’s platform.
– Glooko’s platforms are compatible with over 95 percent of diabetes devices globally, and the Lilly collaboration expands upon the Company’s device-agnostic model for remote patient monitoring and patient data management. This gives patients and their healthcare providers more freedom of choice for managing their care.
Photo: Martin Barraud/Getty Images
Pharma giant Eli Lilly has inked a series of deals with four diabetes management companies to integrate with its forthcoming Tempo Pen and Tempo Smart Button products.
The companies that signed strategic international agreements with Eli Lilly are Dexcom, Glooko, myDiabby Healthcare and Roche.
Through the agreements, Eli Lilly’s Tempo Pen and connected Tempo Smart Button will integrate with the software platforms and/or medical devices offered by the diabetes management companies to allow for the collection and sharing of personal health data. We re pleased to work alongside these innovative partners who share our commitment to improving diabetes outcomes by bringing together medicine and digital solutions for the global diabetes community, Marie Schiller, vice president of product development for Connected Care and Insulins at Eli Lilly, said in a statement.
06 maggio 2021 12:51
Fonte: Adnkronos
#salute-e-benessere
- Roche and Lilly will integrate data from Lilly s connected insulin pen solution into the mySugr app in several countries.
- Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals.
- By collaborating with Lilly, Roche accelerates growth of its open ecosystem enabling its strategy of integrated Personalised Diabetes Management (iPDM).
BASEL, Switzerland, May 6, 2021 /PRNewswire/ Roche today announced that it has signed a collaboration agreement with Eli Lilly and Company, a global leader in diabetes care delivering innovative solutions including medicines and technologies, to work towards optimising the management of insulin pen therapy. By collaborating with Lilly, Roche follows its ambition to create an open ecosystem including its own and partner devices, solutions and services, a
Eli Lilly: accords avec quatre entreprises autour du diabèt abcbourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abcbourse.com Daily Mail and Mail on Sunday newspapers.